Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Posthoc data analysis from the phase 3 randomize d, open-lab el study comparing trab ecte din and PLD versus PLD alone in patients with recurrent ovarian cancer

被引：1
|
作者：
Monk, Bradley J. [1 ]
Herzog, Thomas J. [2 ]
Wang, George [3 ]
Triantos, Spyros [3 ]
Maul, Scott [4 ]
Knoblauch, Roland [3 ]
McGowan, Tracy [5 ]
Shalaby, Waleed S. W. [5 ]
Coleman, Robert L. [6 ]
机构：
[1] Creighton Univ, Univ Arizona, US Oncol Network, Arizona Oncol, Phoenix, AZ 85012 USA
[2] Univ Cincinnati, Canc Ctr, Cincinnati, OH USA
[3] Janssen Res & Dev, Spring House, PA USA
[4] Janssen Res & Dev, Los Angeles, CA USA
[5] Janssen Sci Affairs LLC, Horsham, PA USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
DATA IN BRIEF | 2020年 / 30卷
关键词：
Overall survival; Pegylated liposomal doxorubicin; Trabectedin; Recurrent ovarian cancer; Response rate;
D O I：
10.1016/j.dib.2020.105465
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
The data presented herein are supplementary to our published primary article "A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer"[1]. The exploratory analysis evaluated the impact of prior pegylated liposomal doxorubicin (PLD) therapy in patients who participated in a randomized, open-label study comparing combination therapy of trabectedin and PLD vs PLD alone in third-line recurrent ovarian cancer (ROC). These exploratory analyses showed that prior treatment with PLD in ROC does not impact the response and survival rates nor does it increase toxicities or negatively influence survival and response rates in both treatment groups. (C) 2020 The Author(s). Published by Elsevier Inc.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD
    Poveda, A.
    Kaye, S. B.
    McCormack, R. T.
    Wang, S.
    Ricci, D.
    Broderick, E.
    Parekh, T.
    Lebedinsky, C.
    Tecero, J. C.
    Monk, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] AN OBSERVATIONAL, MULTICENTER, PROSPECTIVE STUDY OF TRABECTEDIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (PSROC)
    Reichert, D.
    Wimberger, P.
    Ringsdorf, U.
    Krohn, M.
    Kuther, M.
    Runnebaum, I.
    Sehouli, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 558 - 558
  • [23] AN OBSERVATIONAL, MULTICENTER, PROSPECTIVE STUDY OF TRABECTEDIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (PSROC)
    Reichert, D.
    Wimberger, P.
    Ringsdorf, U.
    Krohn, M.
    Kuther, M.
    Runnebaum, I.
    Sehouli, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1717 - 1717
  • [24] An observational, multicenter, prospective study of trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC)
    Reichert, D.
    Wimberger, P.
    Ringsdorf, U.
    Krohn, M.
    Runnebaum, I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] A PHASE 1B STUDY OF TREBANANIB (AMG 386) IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) OR TOPOTECAN (T) IN WOMEN WITH RECURRENT OVARIAN CANCER
    Wong, Shirley S.
    Ananda, Sumitra
    Vergote, Ignace B.
    Schilder, Russell J.
    Pippitt, Charles H.
    Scudder, Sidney
    Nanayakkara, Nuwan
    Adewoye, Henry
    Melara, Rebeca
    Wenham, Robert M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 316 - 317
  • [26] Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer
    Matulonis, U. A.
    Barry, W.
    Penson, R. T.
    Konstantinopoulos, P. A.
    Luo, W.
    Hoffman, M. A.
    Horowitz, N. S.
    Farooq, S.
    Dizon, D. S.
    Stover, E.
    Wright, A. A.
    Campos, S. M.
    Krasner, C.
    Liu, J. F.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 24 - 24
  • [27] Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone
    Krasner, C. N.
    Poveda, A.
    Herzog, T.
    Vermorken, J.
    Monk, B.
    Zintl, P.
    Li, J.
    Su, Y.
    Dhawan, R.
    Kaye, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] A randomized double-blind phase III trial comparing vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD plus placebo in patients with platinum-resistant ovarian cancer (PROCEED).
    Naumann, R. Wendel
    Gilbert, Lucy
    Miller, Anthonette M.
    Ma, Hong
    Ghamande, Sharad A.
    Vergote, Ignace
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] A phase III study of trabectedin (T) plus pegylated liposomal doxorubicin (PLD) versus PLD for treatment of advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Coleman, Robert L.
    Monk, Bradley J.
    Knoblauch, Roland Elmar
    Parekh, Trilok V.
    Triantos, Spyros
    Maul, Raymond Scott
    Park, Youn Choi
    Herzog, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)
    O'Cearbhaill, R. E.
    Wolfer, A.
    Disilvestro, P.
    O'Malley, D. M.
    Sabbatini, P.
    Shohara, L.
    Schwarzenberger, P. O.
    Ricciardi, T.
    Macri, M.
    Ryan, A.
    Venhaus, R. R.
    Bryan, J. K.
    Wong, P.
    Homicsko, K.
    Kandalaft, L.
    Rusakiewicz, S.
    Harari, A.
    Monk, B. J.
    Coukos, G.
    ANNALS OF ONCOLOGY, 2018, 29
12345